fashion -WSS

fashion

author：hotspot 2025-10-01 23:39:05 - browse：96

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： How climate

WSS

Hospital price transparency does save money, advocate argues

Nick Jonas talks about managing diabetes along with his career

Why health workers in Gaza are injured or die at high rates

Female surgeons have lower rates of long

Solve the antibiotic resistance crisis with preventive drugs

NIH confirmation hearing shows politicization of research

Wikipedia

fashion

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Massive project maps cells in human brain in unprecedented detail

Virginia high school admissions case could be legal follow

Beam Therapeutics to lay off 20% of its staff, re

At least 13 dead in Texas as scorching temps continue

Female surgeons have lower rates of long

Continuity nursing helped my family in our darkest PICU moments

Hospital price transparency does save money, advocate argues

Drug repurposing or repositioning? The language matters

Massive project maps cells in human brain in unprecedented detail

hotspot

Studies point to risks of excluding people with obesity from drug trials

A revolution in caring for preterm infants

How clinical AI models' predictive power can degrade over time

Life sciences deals on track to hit lowest point since 2017

Senate committee scrutinizes Medicare Advantage brokers

Peter Marks talks Operation Warp Speed for Rare Diseases

focus

focus

explore

hotspot